G&S Capital
DGX icon

G&S Capital’s Quest Diagnostics DGX Stock Holding History

G&S Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.48M Sell
6,341
-8,767
-58% -$2.03M 0.43% 67
2026
Q2 		$3.2M Sell
15,108
-184
-1% -$36.1K 0.93% 38
2026
Q1 		$3M Buy
15,292
+179
+1% +$34.8K 1.05% 36
2025
Q4 		$2.62M Sell
15,113
-136
-0.9% -$24.8K 0.93% 43
2025
Q3 		$2.91M Buy
15,249
+8,225
+117% +$1.46M 1.07% 32
2025
Q2 		$1.26M Buy
+7,024
New +$1.22M 0.5% 63

Other funds holding DGX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

G&S Capital's DGX Position: Q3 2026 in Review

G&S Capital reduced its Quest Diagnostics (DGX) stake by 58% in Q3 2026, selling an estimated $2.03M and leaving 6,341 shares worth $1.48M. The position accounts for 0.43% of the portfolio, ranked #67.

G&S Capital first reported a position in DGX in Q2 2025 and has held it in 6 quarters since. The position peaked at $3.2M in Q2 2026. 978 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • G&S Capital held 6,341 shares of Quest Diagnostics worth $1.48M as of Q3 2026.
  • G&S Capital sold 8,767 Quest Diagnostics shares in Q3 2026, an estimated $2.03M.
  • Quest Diagnostics made up 0.43% of G&S Capital's portfolio in Q3 2026, its #67 holding.
  • G&S Capital first reported a position in Quest Diagnostics in Q2 2025 and has held it in 6 quarters since.
  • G&S Capital's Quest Diagnostics position peaked at $3.2M in Q2 2026.
  • 978 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on G&S Capital's 13F filing for Q3 2026, filed 23 Oct 2026.